<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797988</url>
  </required_header>
  <id_info>
    <org_study_id>D0000000160</org_study_id>
    <nct_id>NCT04797988</nct_id>
  </id_info>
  <brief_title>Eon® Flanks Safety Clinical Study Protocol</brief_title>
  <official_title>Eon® Flanks Safety Clinical Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dominion Aesthetic Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dominion Aesthetic Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide objective evidence regarding the safety of eon® treatment&#xD;
      of the flanks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to provide objective evidence regarding the safety of eon® treatment&#xD;
      of the flanks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2021</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Evaluation eon® treatment of the flanks (Adverse Events)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Adverse Events will be assessed to include ultrasound evaluations with a single expert sonographer identifying the pre-treatment versus Week 2 post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>Subject Questionnaires will be completed by subjects at the end of the study to determine subject satisfaction with the procedure. Subjects will respond using a scale of 1-6, with 1 being extremely satisfied and 6 being extremely dissatisfied.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Adipose Tissue</condition>
  <arm_group>
    <arm_group_label>eon FR 1064 nm Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be treated with the eon FR 1064 nm device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eon® FR 1064 nm device</intervention_name>
    <description>The subject will be treatment area - flanks, will be treated with the eon device.</description>
    <arm_group_label>eon FR 1064 nm Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a healthy male or female &gt; 18 years or older seeking treatment for unwanted&#xD;
             fat in the flanks.&#xD;
&#xD;
               -  Subject must be able to read, understand and sign the Informed Consent Form (ICF)&#xD;
                  in English.&#xD;
&#xD;
               -  Subject has sufficient thickness (≥ 20 mm) of adipose tissue on the flanks area.&#xD;
&#xD;
               -  Subject must be willing and able to adhere to the treatment and follow-up visit&#xD;
                  schedule.&#xD;
&#xD;
               -  Subject is willing to have photographs and ultrasound measurements taken of the&#xD;
                  treated area.&#xD;
&#xD;
               -  Female subjects must be using medically acceptable form of birth control during&#xD;
                  the entire course of the study or may be post-menopausal, or surgically&#xD;
                  sterilized.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Subject had an aesthetic fat reduction procedure in the treatment area within the&#xD;
             previous year&#xD;
&#xD;
               -  Subject was pregnant in the last 3 months, intending to become pregnant,&#xD;
                  postpartum or nursing in last 6 months&#xD;
&#xD;
               -  Subject has an infection, dermatitis or a rash in the treatment area.&#xD;
&#xD;
               -  Subject has tattoos or jewelry in the treatment area or within the treatment area&#xD;
                  site or photography frame.&#xD;
&#xD;
               -  Subject has a history of keloid scarring, hypertrophic scarring or of abnormal&#xD;
                  wound healing.&#xD;
&#xD;
               -  Subject has a history of immunosuppression/immune deficiency disorders or&#xD;
                  currently using immunosuppressive medications.&#xD;
&#xD;
               -  Subject has a history of a known bleeding disorder.&#xD;
&#xD;
               -  Subject has a known photosensitivity to the study laser wavelength, history of&#xD;
                  ingesting medications known to induce photosensitivity, or history of seizure&#xD;
                  disorders due to light.&#xD;
&#xD;
               -  Subject has known collagen, vascular disease or scleroderma.&#xD;
&#xD;
               -  Subject has undergone a surgery or procedure in the treatment area within 6&#xD;
                  months of treatment, which is still healing.&#xD;
&#xD;
               -  Subject suffers from significant concurrent illness, such as insulin-dependent&#xD;
                  diabetes, peripheral vascular disease or peripheral neuropathy.&#xD;
&#xD;
               -  Subject is undergoing systemic chemotherapy for the treatment of cancer.&#xD;
&#xD;
               -  Subject is using gold therapy for disorders such as rheumatologic disease or&#xD;
                  lupus.&#xD;
&#xD;
               -  Subject has participated in a study of another device or drug within three months&#xD;
                  prior to enrollment or during the study.&#xD;
&#xD;
               -  As per the investigator's discretion, the subject has any physical or mental&#xD;
                  condition which might make it unsafe for the subject to participate in this&#xD;
                  study.&#xD;
&#xD;
               -  Subject has ongoing use of steroids or secondary rheumatoid drugs.&#xD;
&#xD;
               -  Subject is actively taking psychotropic medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fiala Aesthetics</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

